InflaRx Announces Participation in February Investor Conferences

InflaRx (Nasdaq: IFRX) will participate in investor conferences in February 2026, offering live presentations and one-on-one meetings.

Rhea-AI Summary

InflaRx (Nasdaq: IFRX) will participate in investor conferences in February 2026, offering live presentations and one-on-one meetings. Key appearances include a fireside chat at the Guggenheim Biotech Summit on Feb 11, 2026 at 11:30 AM ET and a virtual presentation at Oppenheimer on Feb 25, 2026 at 8:40 AM ET. Replay links and details for one-on-one meetings are available from the company. The release also summarizes InflaRx's lead programs, izicopan and vilobelimab, and corporate locations in Germany and the U.S.

Argus Jan 29 session

+1.30% close to close Open Argus

Details

News Market Reaction – IFRX

On Jan 29, the day this news came out, IFRX closed 1.30% above the previous close.

Data tracked by StockTitan Argus for the Jan 29 session.

Key Figures

Guggenheim summit dates: February 11–12, 2026 Guggenheim fireside time: 11:30 AM ET Oppenheimer conference dates: February 25–26, 2026 +2 more

Guggenheim summit dates

February 11–12, 2026

Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Guggenheim fireside time

11:30 AM ET

Fireside chat on Wednesday, February 11

Oppenheimer conference dates

February 25–26, 2026

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Oppenheimer presentation time

8:40 AM ET

Virtual presentation on February 25

Founding year

2007

InflaRx was founded in 2007

Historical Context

5 past events · Latest: Jan 08

5 events

1. Jan 08

   Cost-cutting strategy

   24h Move

   -9.2%

   Refocus on izicopan with ~30% workforce reduction and extended cash runway.

2. Dec 30

   Phase 3 data update

   24h Move

   +0.0%

   Terminated Phase 3 vilobelimab PG study with mixed primary and post-hoc results.

3. Dec 11

   Drug naming, data recap

   24h Move

   -2.9%

   WHO INN ‘izicopan’ announcement with supportive tolerability and activity signals.

4. Nov 10

   Positive Phase 2a data

   24h Move

   +28.5%

   Topline INF904 Phase 2a data in HS and CSU showing clinical activity and safety.

5. Nov 07

   Data timing and webcast

   24h Move

   +2.5%

   Announcement of upcoming Phase 2a topline data and Q3 results timing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

complement system, anti-c5a, c5a, c5ar, +3 more

7 terms

complement system medical

"pioneering anti-inflammatory therapeutics by targeting the complement system"

The complement system is a set of proteins in the blood that act together like a security alarm and cleanup crew for the body’s immune system: they detect threats, tag invaders for removal, and help destroy harmful cells. Investors should care because drugs or diagnostics that target or measure this system can affect treatment effectiveness, safety profiles, and market potential for therapies in immune, inflammatory, and rare disease areas.

anti-c5a medical

"applying its proprietary anti-C5a and anti-C5aR technologies"

Anti-C5a is an antibody or small-molecule drug that blocks C5a, a naturally occurring protein that can trigger intense inflammation as part of the immune response; by neutralizing C5a the therapy aims to reduce harmful immune overreactions. For investors, anti-C5a candidates matter because positive clinical results can create new treatments for severe infections, autoimmune flares or inflammation-driven conditions, affecting a developer’s regulatory milestones, market potential and stock value—think of it as a medical brake on runaway inflammation.

c5a medical

"complement activation factor C5a and its receptor, C5aR"

C5a is a small protein produced by the immune system that acts like an alarm bell, signaling and attracting immune cells to sites of infection or injury and triggering inflammation. Investors care because excessive or uncontrolled C5a activity is linked to many inflammatory and autoimmune diseases, making it a common target for drugs and diagnostics; treatments that block or measure C5a can affect clinical outcomes, regulatory approval prospects, and commercial value in biotech and pharmaceutical portfolios.

c5ar medical

"anti-C5a and anti-C5aR technologies to discover, develop and commercialize"

C5aR is a protein on the surface of immune cells that senses and responds to a small immune signaling molecule called C5a; when activated it acts like a doorbell that calls immune cells and ramps up inflammation. It matters to investors because drugs that block or modulate this receptor can reduce harmful inflammation in diseases, so clinical trial results, approvals, or setbacks for C5aR-targeting therapies can materially affect a biotech’s value and market prospects.

pk/pd medical

"has shown promising PK/PD characteristics as well as therapeutic potential"

PK/PD stands for pharmacokinetics and pharmacodynamics: PK describes how a drug moves through the body — how it is absorbed, distributed, broken down and eliminated — while PD describes the drug’s effects on the body and how those effects change with dose. For investors, strong PK/PD data help predict whether a drug can be dosed safely and effectively, shape clinical trial success, regulatory approval chances and commercial potential, much like knowing both delivery speed and the strength of a message before choosing a shipping method.

hidradenitis suppurativa medical

"developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa"

A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.

monoclonal antibody medical

"vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows:

Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 11 - 12, 2026 in New York, NY
Fireside chat on Wednesday, February 11 at 11:30 AM ET

InflaRx will also conduct one-on-one investor meetings on February 11^th. A link to view the fireside chat live stream and its replay is available here.

Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 25 - 26, 2026 in a virtual format
Virtual presentation on February 25 at 8:40 AM ET

InflaRx will also conduct one-on-one investor meetings on February 25^th. A link to view the virtual presentation and its replay is available here.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is InflaRx presenting at the Guggenheim Biotech Summit (IFRX)?

InflaRx will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 with a fireside chat at 11:30 AM ET. According to InflaRx, the company will also hold one-on-one investor meetings the same day and provide a webcast and replay link.

What time is the InflaRx (IFRX) virtual presentation at the Oppenheimer conference?

InflaRx will present virtually at the Oppenheimer Healthcare Life Sciences Conference on Feb 25, 2026 at 8:40 AM ET. According to InflaRx, the presentation will be available via a virtual stream and a replay link for investors.

How can investors watch InflaRx's (IFRX) fireside chat and presentation replays?

Investors can view live streams and replays via links provided by InflaRx for each conference appearance. According to InflaRx, links to the fireside chat and the virtual presentation replay are available through the company.

Will InflaRx (IFRX) hold one-on-one investor meetings at the February conferences?

Yes. InflaRx will conduct one-on-one investor meetings on both Feb 11 and Feb 25, 2026 alongside its presentations. According to InflaRx, these meetings are scheduled in conjunction with the Guggenheim and Oppenheimer events.

What clinical programs will InflaRx (IFRX) likely discuss at the February 2026 events?

InflaRx is expected to highlight lead programs izicopan (INF904) and vilobelimab, including clinical-stage results and development plans. According to InflaRx, izicopan has shown PK/PD and therapeutic potential in Phase 1 and Phase 2a studies.

Where is InflaRx (IFRX) headquartered and where are its offices located?

InflaRx was founded in 2007 and has offices in Jena and Munich, Germany, plus Ann Arbor, Michigan, USA. According to InflaRx, its group includes German and U.S. subsidiaries under InflaRx N.V.